Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aktis Oncology, Inc. - Common stock (NQ:AKTS)

18.52 -0.95 (-4.88%)
Delayed Quote Updated: 4:00 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aktis Oncology, Inc. - Common stock

< Previous 1 2 3 Next >
News headline image
Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3
From Aktis Oncology Inc.
Via GlobeNewswire
News headline image
Aktis Oncology to Present at Upcoming September Investor Conferences
From Aktis Oncology Inc.
Via GlobeNewswire
News headline image
Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026
From Aktis Oncology Inc.
Via GlobeNewswire
News headline image
Aktis Oncology to Present at the Jefferies Global Healthcare Conference
From Aktis Oncology Inc.
Via GlobeNewswire
News headline image
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors
From Aktis Oncology Inc.
Via GlobeNewswire
News headline image
Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026
From Aktis Oncology Inc.
Via GlobeNewswire
News headline image
Aktis Oncology to Present at the BofA Securities Health Care Conference
From Aktis Oncology Inc.
Via GlobeNewswire
News headline image
Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
From Aktis Oncology Inc.
Via GlobeNewswire
News headline image
Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
From Aktis Oncology Inc.
Via GlobeNewswire
News headline image
Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors
From Aktis Oncology Inc.
Via GlobeNewswire
News headline image
Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results
From Aktis Oncology Inc.
Via GlobeNewswire
News headline image
Aktis Oncology to Present at Upcoming March Investor Conferences
From Aktis Oncology Inc.
Via GlobeNewswire
News headline image
Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate
From Aktis Oncology Inc.
Via GlobeNewswire
News headline image
Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Aktis Oncology Inc.
Via GlobeNewswire
News headline image
Akoustis to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process
Committed to Full Continuity in Delivering Next-Generation BAW High-Band RF Filters to Customers Around the World Filing to Ensure Business Sold Free and Clear of Qorvo Infringement Following Final... 
From Akoustis, Inc.
Via GlobeNewswire
News headline image
Akoustis to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process
From Akoustis, Inc.
Via Business Wire
Stocks Under Ten Cents to Watch in October 2024 CNSP, QLGN, AKTS, CBDW, RJDG
Via AB Newswire
News headline image
Akoustis Receives an Additional Purchase Order for $13 Million XBAW® Filters from Existing Tier-1 Customer
From Akoustis, Inc.
Via GlobeNewswire
News headline image
Akoustis Announces Leadership Transition
From Akoustis, Inc.
Via GlobeNewswire
News headline image
Akoustis Secures $8 Million in Volume XBAW® Orders with Tier-1 Customer
From Akoustis, Inc.
Via GlobeNewswire
News headline image
Akoustis Receives $2 Million in Volume Orders for Wi-Fi 7 Program from Tier-1 Carrier
From Akoustis, Inc.
Via GlobeNewswire
News headline image
Akoustis Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Akoustis, Inc.
Via GlobeNewswire
News headline image
Akoustis Completes Rollout of its XBAW® Design Updates
From Akoustis, Inc.
Via GlobeNewswire
News headline image
Akoustis Reports Third Quarter FY24 Results
From Akoustis, Inc.
Via GlobeNewswire
News headline image
Akoustis to Webcast Q3FY24 Results on May 13 at 8:00 am ET
From Akoustis, Inc.
Via GlobeNewswire
News headline image
Akoustis Receives Two Design Wins with Tier-1 Network Infrastructure Customer
From Akoustis, Inc.
Via GlobeNewswire
News headline image
Akoustis Secures Design Win and Volume Orders for Wi-Fi 7 Solution with Tier-1 Enterprise Class OEM
From Akoustis, Inc.
Via GlobeNewswire
News headline image
Akoustis Introduces Two New 2.4 GHz BAW RF Filters for Wi-Fi Automotive and Access Point Applications
From Akoustis, Inc.
Via GlobeNewswire
News headline image
Akoustis to Attend the 36th Annual Roth Conference on March 17-19, 2024
From Akoustis, Inc.
Via GlobeNewswire
News headline image
Akoustis to Attend GOMACTech 2024 in Charleston from March 19-20
From Akoustis, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS